Physician profile
Kelly E Farris
NPI 1710978655
$5,533.80
in general payments reported to CMS, 2019-2025
31 companies · $909 in 2025
The $909 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $525 · 2021: $1,035 · 2022: $581 · 2023: $1,018 · 2024: $1,094 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,021.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $954.04 | 2021-2025 | |
| Lilly USA, LLC | $701.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $629.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $516.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $403.94 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $291.50 | 2023-2025 | |
| Exact Sciences Corporation | $275.17 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $227.62 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.04 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $162.33 | 2019-2023 | Belsomra, Steglatro |
| Idorsia Pharmaceuticals US INC | $115.52 | 2022-2024 | Quviviq |
| Amgen INC. | $115.03 | 2021-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $110.41 | 2020-2023 | |
| Microport Orthopedics INC | $105.02 | 2019 | |
| Dexcom, INC. | $102.45 | 2023-2024 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $84.31 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.58 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $60.65 | 2021 | |
| Abiomed | $60.19 | 2024 | Impella |
| Biohaven Pharmaceutical Holding Company LTD. | $59.12 | 2022 | |
| Adlon Therapeutics L.P. | $42.67 | 2021 | |
| Coloplast Corp | $42.15 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $29.48 | 2025 | Zoryve |
| Sanofi Pasteur INC. | $23.42 | 2025 | |
| Tolmar, INC. | $23.20 | 2025 | Jatenzo |
| Paratek Pharmaceuticals, INC. | $20.96 | 2021 | |
| Neos Therapeutics, LP | $20.70 | 2024 | Adzenys Xr-Odt |
| Dynavax Technologies Corporation | $19.75 | 2024 | Heplisav-B |
| Genentech USA, INC. | $18.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.22 | 2024 | Trintellix |
| Eisai INC. | $13.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Farris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.